Sunitinib synergizes the antitumor effect of cisplatin via modulation of ERCC1 expression in models of gastric cancer

Cancer Letters

Volumn 321, Issue 2, 2012, Pages 128-136

  Yoon, Young Kwang ^a   Im, Seock Ah ^a,b   Min, Ahrum ^a   Kim, Hwang Phill ^a   Hur, Hyung Seok ^a   Lee, Kyung Hun ^b   Han, Sae Won ^b   Song, Sang Hyun ^a   Youn Oh, Do ^a,b   Kim, Tae You ^a,b,c   Ho Kim, Woo ^a,b   Bang, Yung Jue ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Chemosensitizer; PDGFRA overexpression; Sunitinib

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR XENOGRAFT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG SYNERGISM; ENDONUCLEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; STOMACH NEOPLASMS;

EID: 84862809405     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.019     Document Type: Article

References (41)

1. Bailar J.C., Gornik H.L. Cancer undefeated. N. Engl. J. Med. 1997, 336:1569-1574.
2. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
3. Krause S., Forster Y., Kraemer K., Fuessel S., Kotzsch M., Schmidt U., Wirth M.P., Meye A., Schwenzer B. Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin. J. Urol. 2005, 174:328-331.
4. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-1175.
5. Blansfield J.A., Caragacianu D., Alexander H.R., Tangrea M.A., Morita S.Y., Lorang D., Schafer P., Muller G., Stirling D., Royal R.E., Libutti S.K. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin. Cancer Res. 2008, 14:270-280.
6. Castillo-Avila W., Piulats J.M., Garcia Del Muro X., Vidal A., Condom E., Casanovas O., Mora J., Germa J.R., Capella G., Villanueva A., Vinals F. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors. Clin. Cancer Res. 2009, 15:3384-3395.
7. Sonpavde G., Jian W., Liu H., Wu M.F., Shen S.S., Lerner S.P. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol. Oncol. 2009, 27:391-399.
8. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
9. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 23:1011-1027.
10. O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W., Wong L.M., Hong W., Lee L.B., Town A., Smolich B.D., Manning W.C., Murray L.J., Heinrich M.C., Cherrington J.M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597-3605.
11. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat. Rev. Drug Discov. 2007, 6:734-745.
12. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2003, 2:471-478.
13. Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9:327-337.
14. Prenen H., Cools J., Mentens N., Folens C., Sciot R., Schoffski P., Van Oosterom A., Marynen P., Debiec-Rychter M. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin. Cancer Res. 2006, 12:2622-2627.
15. Robert N.J., Saleh M.N., Paul D., Generali D., Gressot L., Copur M.S., Brufsky A.M., Minton S.E., Giguere J.K., Smith J.W., Richards P.D., Gernhardt D., Huang X., Liau K.F., Kern K.A., Davis J. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin. Breast Cancer 2011, 11:82-92.
16. Faivre S., Delbaldo C., Vera K., Robert C., Lozahic S., Lassau N., Bello C., Deprimo S., Brega N., Massimini G., Armand J.P., Scigalla P., Raymond E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 2006, 24:25-35.
17. Reck M., Frickhofen N., Cedres S., Gatzemeier U., Heigener D., Fuhr H.G., Thall A., Lanzalone S., Stephenson P., Ruiz-Garcia A., Chao R., Felip E. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 2010, 70:180-187.
18. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., Oudard S., Negrier S., Szczylik C., Kim S.T., Chen I., Bycott P.W., Baum C.M., Figlin R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356:115-124.
19. Demetri G.D., van Oosterom A.T., Garrett C.R., Blackstein M.E., Shah M.H., Verweij J., McArthur G., Judson I.R., Heinrich M.C., Morgan J.A., Desai J., Fletcher C.D., George S., Bello C.L., Huang X., Baum C.M., Casali P.G. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
20. Polyzos A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J. Steroid Biochem. Mol. Biol. 2008, 108:261-266.
21. Goodman V.L., Rock E.P., Dagher R., Ramchandani R.P., Abraham S., Gobburu J.V., Booth B.P., Verbois S.L., Morse D.E., Liang C.Y., Chidambaram N., Jiang J.X., Tang S., Mahjoob K., Justice R., Pazdur R. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 2007, 13:1367-1373.
22. Cumashi A., Tinari N., Rossi C., Lattanzio R., Natoli C., Piantelli M., Iacobelli S. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett. 2008, 270:229-233.
23. Guerin O., Formento P., Lo Nigro C., Hofman P., Fischel J.L., Etienne-Grimaldi M.C., Merlano M., Ferrero J.M., Milano G. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J. Cancer Res. Clin. Oncol. 2008, 134:51-57.
24. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics. CA Cancer J. Clin. 2002, 52(2002):23-47.
25. Shin H.R., Jung K.W., Won Y.J., Kong H.J., Yim S.H., Sung J., Seo S.W., Kim K.Y., Lee S.Y., Kong I.S., Hwang I.K., Lee C.W., Woo Z.H., Lee T.Y., Choi J.S., Yoo C.I., Bae J.M., Yoo K.Y. National cancer incidence for the year 2002 in Korea. Cancer Res. Treatment 2002, 39(2007):139-149.
26. Wagner A.D., Grothe W., Haerting J., Kleber G., Grothey A., Fleig W.E. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J. Clin. Oncol. 2006, 24:2903-2909.
27. Kim N.K., Park Y.S., Heo D.S., Suh C., Kim S.Y., Park K.C., Kang Y.K., Shin D.B., Kim H.T., Kim H.J., et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993, 71:3813-3818.
28. Ajani J.A. Evolving chemotherapy for advanced gastric cancer. Oncologist 2005, 10(Suppl. 3):49-58.
29. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Ruschoff J., Kang Y.K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
30. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance. the role of DNA repair pathways. Clin. Cancer Res. 2008, 14:1291-1295.
31. Sancar A. Mechanisms of DNA excision repair. Science 1994, 266:1954-1956.
32. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., Taranchon E., Filipits M., Pirker R., Popper H.H., Stahel R., Sabatier L., Pignon J.P., Tursz T., Le Chevalier T., Soria J.C. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 2006, 355:983-991.
33. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., Vinolas N., Paz-Ares L., Lopez-Vivanco G., Munoz M.A., Felip E., Alberola V., Camps C., Domine M., Sanchez J.J., Sanchez-Ronco M., Danenberg K., Taron M., Gandara D., Rosell R. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 2007, 25:2747-2754.
34. Chiu T.J., Chen C.H., Chien C.Y., Li S.H., Tsai H.T., Chen Y.J. High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. J. Transl. Med. 2011, 9:31.
35. Ku J.L., Park J.G. Biology of SNU cell lines. Cancer Res. Treat. 2005, 37:1-19.
36. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D., Fletcher C.D., Fletcher J.A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299:708-710.
37. Yoon Y.K., Kim H.P., Han S.W., Hur H.S., Oh Do Y., Im S.A., Bang Y.J., Kim T.Y. Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells. Mol. Cancer Ther. 2009, 8:2526-2536.
38. Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M., Sakamoto S., Miura Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int. J. Cancer 1992, 50:604-610.
39. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J. Clin. 2002, 55(2005):74-108.
40. Ohtsu A., Shah M.A., Van Cutsem E., Rha S.Y., Sawaki A., Park S.R., Lim H.Y., Yamada Y., Wu J., Langer B., Starnawski M., Kang Y.K. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J. Clin. Oncol. 2011, 29:3968-3976.
41. K.W. Lee, S.R. Park, D.Y. Oh, Y.L. Park, S.Y. Lee, R. Khosravan, X. Lin, O. Valota, M.J. Lechuga, Y.J. Bang, Sunitinib with capecitabine and cisplatin or capecitabine and oxaliplatin in advanced gastric cancer - a phase I, dose-finding study, in: The 9th international gastric cancer congress, 2011, FP 19-6.